预约演示
更新于：2025-07-20
Droperidol
氟哌利多
更新于：2025-07-20
概要
基本信息
药物类型 小分子化药 |
别名 1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone、1-(1-(4-(p-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone、Droperidol (JP17/USP/INN) + [10] |
作用方式 拮抗剂 |
作用机制 D2 receptor拮抗剂(多巴胺D2受体拮抗剂) |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1970-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H22FN3O2 |
InChIKeyRMEDXOLNCUSCGS-UHFFFAOYSA-N |
CAS号548-73-2 |
关联
37
项与 氟哌利多 相关的临床试验ChiCTR2500097291
Effect of droperidol on postoperative nausea and vomiting in patients undergoing bariatric surgery: a single-center, prospective, randomized controlled study
NCT06726811
Low-Dose Droperidol and Its Association with QTc Interval Changes in Emergency Department Patients
ChiCTR2400081794
Effects of dexmedetomidine combined with low-dose droperidol on postoperative nausea and vomiting in patients undergoing laparoscopic surgery
100 项与 氟哌利多 相关的临床结果
登录后查看更多信息
100 项与 氟哌利多 相关的转化医学
登录后查看更多信息
100 项与 氟哌利多 相关的专利（医药）
登录后查看更多信息
3,445
项与 氟哌利多 相关的文献（医药）2025-10-01TOXICOLOGY IN VITRO
CiPA-qualified human iPSC-derived cardiomyocytes: A new frontier in toxicity testing by evaluating drug-induced arrhythmias
Article
作者: Sarkar, Jaganmay ; Khanna, Amit ; Bhanushali, Paresh ; Lickiss, Bettina ; Linder, Peter ; More, Shruti ; Konala, Vijay Bhaskar Reddy ; Kuhikar, Rutuja ; Gossmann, Matthias
Drug-induced arrhythmias remain a significant challenge in drug development, often leading to serious cardiovascular complications and the withdrawal of approved drugs from the market. The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative aims to enhance cardiac safety assessment by leveraging human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). In this study, we evaluated the effects of 28 drugs on a well-characterized hiPSC-CMs (YBLiCardio, Yashraj Biotechnology Ltd., Mumbai, India) using Electric Field Potential (EFP) measurements. The CardioExcyte 96 system recorded extracellular signals from 96 wells, functioning similarly to microelectrode arrays. Each drug was tested at four concentrations, and the effects were analyzed based on dynamic changes in beat patterns, with QT prolongation assessed by measuring the interval between the sodium spike and T-wave. Our results demonstrated that YBLiCardio cells responded to all drugs in line with the findings from the HESI CiPA study. Notably, droperidol (173 %) and domperidone (182 %), originally classified as intermediate-risk compounds, were identified as high-risk in our model, consistent with previous findings by Nguyen et al. (2017). Additionally, YBLiCardio showed enhanced predictive accuracy for chlorpromazine. These findings highlight the potential of hiPSC-CMs for proarrhythmia risk assessment within the CiPA framework, complementing ion channel data and in silico modeling approaches. Overall, YBLiCardio provides a robust and physiologically relevant platform for predicting cardiotoxicity, supporting safer and more efficient pre-clinical drug discovery & development.
2025-07-01JOURNAL OF CHROMATOGRAPHY A
Nontargeted screening strategy of chemical residues in animal-derived foods based on endogenous metabolite global annotation and interquartile range filtering by ultrahigh-performance liquid chromatography–high-resolution mass spectrometry
Article
作者: Yang, Jun ; Xu, Guowang ; Lu, Xin ; Chen, Tiantian ; Wang, Xinxin ; Liu, Xinyu ; Zhao, Chunxia ; Liang, Wenying ; Zhang, Yujie
Endogenous components and other experimental background information can interfere with the efficiency of nontargeted screening for unknown chemical residues in complex food matrices. In this study, a new nontargeted screening strategy of chemical residues in animal-derived foods was developed based on endogenous metabolite global annotation and interquartile range (IQR) filtering by ultrahigh-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS). First, endogenous metabolite global annotation was employed to eliminate the majority of endogenous components and their related ion peaks in food from the UHPLC-HRMS data. Second, IQR filtering was evaluated across multiple intercept values under different sample sizes and spiking concentrations based on 72 standards of chemical residues. The evaluation results indicated that chemical residues could be rapidly found after background interference was effectively removed when the sum of the third quartile and 20 times the interquartile range was used as intercept values. By integrating endogenous metabolite global annotation information with IQR filtering, this strategy achieved a total background interference filtering performance of >95 %. Finally, this strategy was applied to screen 13 meat samples. Suspected chemical residues in meat samples were successfully found out and identified by endogenous metabolite global annotation and IQR filtering, and the overall capability for filtering background interference reached 93.1 %. The strategy effectively improved the efficiency of nontargeted screening for unknown chemical residues in animal-derived foods, which can provide a powerful tool for routine risk assessment of food safety.
2025-06-16Clinics and Practice
Administering Parenteral Medications in Managing Patients with Acute Arousal in the Behavioral Assessment Unit of the Emergency Department in Hospital Settings.
Article
作者: Gong, Yiting ; Liyanage, Harshini M ; Boyce, Katy ; Thomas, Naveen ; Koo, Theresa ; Das, Soumitra
Background/Objectives: The administration of parenteral medications is essential in managing acute arousal within the Behavioral Assessment Unit (BAU) of the emergency department (ED), where timely and effective intervention is critical. This study aims to evaluate current practices surrounding the use of parenteral medications for patients with acute agitation, focusing on adherence to protocols, medication safety, documentation accuracy, and patient outcomes. Methods: A retrospective analysis was conducted on 177 cases from December 2023 to February 2024. The study assessed the demographics, diagnoses, treatment protocols, and patient outcomes, with a particular emphasis on the use of parenteral medications such as benzodiazepines and antipsychotics. The relationship between medication administration and involuntary admission, mechanical restraint usage, and patient outcomes was also explored. Results: The majority of patients were aged between 21 and 30 years, and there was a predominance of male patients across both groups. Schizophrenia was the most common diagnosis, with a higher prevalence in the parenteral group (34%) compared to the oral-only group (24%), and personality disorders were more frequent in the parenteral group. Intramuscular (IM) medication administration was strongly associated with the use of mechanical restraint, with patients receiving IM medication being 35 times more likely to require restraint, emphasizing the link between more intensive treatment approaches and behavioral challenges. The most frequently administered medications were diazepam (40.6%) and olanzapine (36.5%), with olanzapine, droperidol, and diazepam most commonly used parenterally. Documentation of physical assessments prior to parenteral administration was present in most cases, though comprehensive evaluations such as ECGs were inconsistently performed. Conclusions: Parenteral medications, including benzodiazepines and antipsychotics, were effective in rapidly stabilizing patients, but the study emphasizes reducing dependency on mechanical restraints. Tailoring treatment to patient characteristics and employing alternative de-escalation strategies can improve safety and align with recovery-oriented care. This study highlights the need for evidence-based practices to optimize care and improve patient outcomes in ED settings. Further research is needed to explore long-term outcomes and refine non-coercive care approaches.
100 项与 氟哌利多 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 1989-01-01 | |
| 麻醉 | 日本 | 1971-05-10 | |
| 恶心和呕吐 | 美国 | 1970-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 32 | (Haloperidol) | 餘餘積繭憲壓鑰積夢窪(獵鹽願獵簾襯積構糧廠) = 憲簾蓋夢膚襯簾鬱築範 獵壓構艱憲窪鏇繭築鑰 (齋範選齋網廠願構鏇蓋, 3.30) 更多 | - | 2025-05-21 | ||
(Droperidol) | 餘餘積繭憲壓鑰積夢窪(獵鹽願獵簾襯積構糧廠) = 鏇繭製築襯衊艱鬱窪蓋 獵壓構艱憲窪鏇繭築鑰 (齋範選齋網廠願構鏇蓋, 3.04) 更多 | ||||||
N/A | 322 | DEX, OND, and placebo | 觸鏇襯鹽選齋襯襯蓋壓(遞製鏇餘餘淵衊構艱簾) = 構鹽膚鹽願簾襯膚簾齋 窪糧鬱鹽繭壓廠廠遞壓 (簾範蓋鬱願網鏇範餘齋 ) | - | 2017-06-01 | ||
DEX, OND, and DRO | 觸鏇襯鹽選齋襯襯蓋壓(遞製鏇餘餘淵衊構艱簾) = 鬱遞鑰夢襯艱醖艱鹹醖 窪糧鬱鹽繭壓廠廠遞壓 (簾範蓋鬱願網鏇範餘齋 ) | ||||||
N/A | - | 淵膚鬱獵鹹鏇齋蓋壓夢(餘顧獵艱鹹糧壓繭鑰餘) = 壓積積窪願膚糧齋遞齋 壓網鹹顧廠鑰鬱襯蓋觸 (淵鹽簾網鑰範製鹹淵製 ) | - | 1991-01-01 | |||
Droperidol + placebo pretreatment | 簾鏇鬱願廠觸窪艱顧顧(膚鏇鬱餘夢壓淵鬱願醖) = 顧鹽構願構鹹淵憲鏇積 艱鏇憲壓糧夢壓鑰選鹹 (鏇淵衊襯鹽衊鏇願鏇簾 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用